Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Breast cancer in Europe • Lumpectomy—treatment of breast cancer PART 05: Market landscape • Market Overview • Market size and forecast • Five forces analysis PART 06: Market segmentation by product • Systems • Surgical tools PART 07: Market segmentation by end-user • Hospitals and integrated breast cancer centers • ASCs PART 08: Geographical segmentation • Breast cancer screening programs in five European countries • France • Germany • Italy • Spain • UK • Others PART 09: Market drivers • Government initiatives to increase public awareness of breast cancer • Increasing adoption of mammography for early breast cancer detection • Increasing number of hospital beds to facilitate cancer diagnosis and treatment PART 10: Impact of drivers PART 11: Market challenges • Reluctance to adopt lumpectomy owing to associated high cost • Unavailability of government programs for younger women • Poor cosmetic results PART 12: Impact of drivers and challenges PART 13: Market trends • Presence of venture capitalists for developing lumpectomy devices • Transformation of marketing and sales strategies for lumpectomy • Emergence of integrated breast cancer treatment centers PART 14: Vendor landscape • Competitive landscape analysis • Focus on companies PART 15: Key vendor analysis • Dune Medical Devices • iCAD • Key companies to watch • Other prominent vendors PART 16: Appendix • List of abbreviations List of Exhibits Exhibit 01: Market assumptions to calculate the market size Exhibit 02: Product offerings Exhibit 03: Breast cancer: Cancer deaths in Europe (2013) Exhibit 04: Lumpectomy procedure Exhibit 05: European countries: Government plans for breast cancer screening programs Exhibit 06: Products and technologies used in invasive lumpectomy procedures Exhibit 07: Products under development: Companies and universities Exhibit 08: Products and technologies used in MI invasive lumpectomy procedures Exhibit 09: Lumpectomy market in Europe 2016-2021 ($ billions) Exhibit 10: Five forces analysis Exhibit 11: Market overview: Systems Exhibit 12: Unmet needs and focus of companies Exhibit 13: Market impact analysis: Systems Exhibit 14: Market overview: Surgical tools Exhibit 15: Unmet needs and focus on companies Exhibit 16: Market impact analysis: Surgical tools Exhibit 17: Lumpectomy market in Europe by end-user 2016 Exhibit 18: Breast cancer screening programs: Five major countries in Europe Exhibit 19: Estimated number of new breast cancer and lumpectomy cases in France 2016-2021 Exhibit 20: Lumpectomy market in France 2016 Exhibit 21: Market overview: France Exhibit 22: Lumpectomy market revenue in France 2016-2021 ($ millions) Exhibit 23: Lumpectomy market by single and re-excision 2016-2021 (%) Exhibit 24: Cost component of lumpectomy procedure Exhibit 25: Estimated number of new breast cancer and lumpectomy cases in Germany 2016-2021 Exhibit 26: Lumpectomy market in Germany 2016 Exhibit 27: Market overview: Germany Exhibit 28: Lumpectomy market revenue in Germany 2016-2021 ($ millions) Exhibit 29: Lumpectomy market by single and re-excision in Germany (by %) Exhibit 30: Cost component of lumpectomy procedure Exhibit 31: Estimated number of new breast cancer and lumpectomy cases in Italy 2016-2021 Exhibit 32: Lumpectomy market in Italy 2016 Exhibit 33: Market overview: Italy Exhibit 34: Lumpectomy market revenue in Italy 2016-2021 ($ millions) Exhibit 35: Lumpectomy market by single and re-excision in Italy (%) Exhibit 36: Cost component of lumpectomy procedure Exhibit 37: Estimated number of new breast cancer and lumpectomy cases in Spain 2016-2021 Exhibit 38: Lumpectomy market in Spain 2016 Exhibit 39: Market overview: Spain Exhibit 40: Lumpectomy market revenue in Spain 2016-2021 ($ millions) Exhibit 41: Lumpectomy market by single and re-excision in Spain (%) Exhibit 42: Cost component of lumpectomy procedure Exhibit 43: Estimated number of new breast cancer and lumpectomy cases in UK 2016-2021 Exhibit 44: Lumpectomy market in UK 2016 Exhibit 45: Market overview: UK Exhibit 46: Lumpectomy market revenue in UK 2016-2021 ($ millions) Exhibit 47: Cost component of lumpectomy procedure Exhibit 48: Lumpectomy market in others 2016 Exhibit 49: Lumpectomy market revenue in others 2016-2021 ($ billions) Exhibit 50: Market overview: Lumpectomy market in Austria Exhibit 51: Market overview: Lumpectomy market in Belgium Exhibit 52: Market overview: Lumpectomy market in Czech Republic Exhibit 53: Market overview: Lumpectomy market in Greece Exhibit 54: Market overview: Lumpectomy market in Netherlands Exhibit 55: Market overview: Lumpectomy market in Portugal Exhibit 56: Market overview: Lumpectomy market in Russia Exhibit 57: Market overview: Lumpectomy market in Sweden Exhibit 58: Market overview: Lumpectomy market in Switzerland Exhibit 59: Awareness programs by EU Exhibit 60: Percentage of women screened for mammography and survival rate of women with breast cancer 2013 (based on OECD 2015) Exhibit 61: Number of hospital beds and discharge of cancer patient per 1,000 inhabitants in 2015 Exhibit 62: Impact of drivers Exhibit 63: Cost component of lumpectomy procedure Exhibit 64: Post-lumpectomy radiation cost Exhibit 65: Age-standard incidence of breast cancer in women below and above 40 years of age in 2013 Exhibit 66: Impact of drivers and challenges Exhibit 67: Market impact analysis: Funding by investors for lumpectomy Exhibit 68: Marketing and sales strategies of large and small companies Exhibit 69: Competitive structure analysis of lumpectomy market in Europe 2016 Exhibit 70: Competitive landscape analysis of lumpectomy market in Europe 2016 Exhibit 71: Strategic focus on new players in the lumpectomy market Exhibit 72: Strategic focus of existing players in the lumpectomy market Exhibit 73: Dune Medical Devices strength assessment Exhibit 74: Dune Medical Devices strategy assessment Exhibit 75: Dune Medical Devices opportunity assessment Exhibit 76: iCAD strength assessment Exhibit 77: iCAD strategy assessment Exhibit 78: iCAD opportunity assessment Exhibit 79: Key companies to watch Exhibit 80: Other prominent vendors

Dune Medical Devices iCAD, ClearCut Medical, Hologic, Medtronic, Sanarus, Vector Surgical, and ZEISS.